TABLE 3.
COVID-19 management and outcomes for hospitalized waitlist and kidney transplant patients
| Waitlisted (n = 46) | Transplant (n = 52) | |
|---|---|---|
| Respiratory supporta | ||
| None | 5/35 (14%) | 16 (31%) |
| Nasal Cannula | 16/33 (48%) | 16 (31%) |
| BiPap/Nonrebreather | 7/33 (21%) | 3 (6%) |
| Intubation | 11/38 (29%)b | 16 (31%) |
| Renal replacement therapy | — | 4/47 (9%) |
| Adjustment in Mycophenolate mofetil dose | ||
| No change | — | 5/47 (11%) |
| Reduced | — | 12/47 (26%) |
| Withheld | — | 30/47 (64%) |
| Azithromycin or Doxycycline | 16/33 (48%) | 18/45 (40%) |
| Additional antibiotics | 27/35 (77%) | 28/44 (64%) |
| Bolus steroids | 4/30 (13%) | 8/45 (18%) |
| Experimental therapies (%) | ||
| Hydroxychloroquine | 18/35 (51%) | 34/45 (76%) |
| Remdesivir | 0/30 (0%) | 6/45 (13%) |
| Tocilizumab | 1/30 (3%) | 2/45 (4%) |
| Selinexor | 0/30 (0%) | 2/45 (4%) |
| Convalescent plasma | 0/30 (0%) | 1/45 (2%) |
| Length of admission, days (IQR) | 11 (5-14) | 9 (5–19) |
| Remains inpatient | 2 (4%) | 1 (1.9%) |
| Graft loss | — | 4/47 (9%) |
| Died | 19 (41%) | 13 (25%) |
a
Indicates the highest level of respiratory support required during hospitalization
b
Included are all patients who were known to be intubated (n = 9) and who were recommended to be intubated but who elected to be DNR/DNI (n = 2). Not included are seven patients who died at other hospitals and presumably were intubated but confirmatory data are not available.